Pretransplant Management of the Cirrhotic Patient

Clinics in Liver Disease

Volumn 11, Issue 2, 2007, Pages 431-449

  Grewal, Priya ^a   Martin, Paul ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMINOGLYCOSIDE; AMOXICILLIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; CISAPRIDE; CLAVULANIC ACID; CYANOACRYLATE; FUROSEMIDE; ILOPROST; ISOSORBIDE MONONITRATE; MIDODRINE; NADOLOL; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN; NORFLOXACIN; OCTREOTIDE; PENTOXYFILLINE; PROPRANOLOL; PROSTACYCLIN; RIFAXIMIN; SPIRONOLACTONE; TERLIPRESSIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ASCITES; BACTERIAL INFECTION; BACTERIAL PERITONITIS; BLEEDING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIET RESTRICTION; DRUG DOSE INCREASE; DRUG HYPERSENSITIVITY; GASTROINTESTINAL HEMORRHAGE; HEPATOPULMONARY SYNDROME; HEPATORENAL SYNDROME; HUMAN; ISCHEMIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; META ANALYSIS; MORTALITY; ORGAN DONOR; OSTEOPENIA; PARACENTESIS; PORTOSYSTEMIC ANASTOMOSIS; PULMONARY HYPERTENSION; REVIEW; STOMACH VARICES; SYSTEMATIC REVIEW; VACCINATION; VARICOSIS; VIRUS INFECTION;

GASTROINTESTINAL HEMORRHAGE; HUMANS; HYPERTENSION, PORTAL; KIDNEY DISEASES; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PERITONITIS;

EID: 34250851530     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2007.04.009     Document Type: Review

References (139)

1. Kozak L.J., Hall M.J., and Owings M.F. National hospital discharge survey: 2000 annual summary with detailed diagnosis and procedure data. National Center for Health Statistics. Vital Health Stat 13 (2002) 1-194
2. United Network for Organ Sharing (UNOS). Donors and Waiting List: 1993-2002 National Data. Available at: http://www.unos.org/data/. Accessed May 2007.
3. Wiesner R.H., Edwards E.B., Freeman R.B., et al. Model for end stage liver disease (MELD) and allocation of donor livers. Gastroenterology 124 (2003) 91-96
4. Trotter J.F., and Osgood M.J. MELD scores of liver transplant recipients according to size of waiting list: impact of organ allocation and patient outcomes. JAMA 291 (2004) 1871-1874
5. D'Amico G., Morabito A., Pagliaro L., et al. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 31 (1986) 468-475
6. Runyon B.A., Montano A.A., Akriviadis E.A., et al. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med 117 (1992) 215-220
7. Epstein S.K., Freeman R.B., Khayat A., et al. Aerobic capacity is associated with 100-day outcome after hepatic transplantation. Liver Transpl 10 (2004) 418-424
8. Stiehm A.J., Mendler M.H., and Runyon B.A. Detection of diuretic-resistance or diuretic-sensitivity by the spot urine Na/K ratio in 729 specimens from cirrhotics with ascites: approximately 90% accuracy as compared to 24-hr urine Na excretion. Hepatology 36 (2002) 222A
9. Runyon B.A. Management of the adult patient with ascites due to cirrhosis. Hepatology 39 (2004) 841-856
10. Runyon B.A. Care of patients with ascites. N Engl J Med 330 (1994) 337-342
11. Runyon B.A. Ascites and spontaneous bacterial peritonitis. In: Feldman M., Friedman L.S., and Sleisenger M.H. (Eds). Sleisenger and Fordtran's gastrointestinal and liver disease. 7th edition (2002), Saunders, Philadelphia 1517-1542
12. Arroyo V., Gines P., Gerbes A.L., et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 23 (1996) 164-176
13. Gines P., Tito L., Arroyo V., et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 94 (1988) 1493-1502
14. Rossle M., Ochs A., Gulberg V., et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 342 (2000) 1701-1707
15. Gines P., Uriz J., Calahorra B., et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 123 (2002) 1839-1847
16. Sanyal A.J., Genning C., Reddy R.K., et al. The North American study for the treatment of refractory ascites. Gastroenterology 124 (2003) 634-641
17. Salerno F., Merli M., Cazzaniga M., et al. Randomized controlled study of TIPS vs. paracentesis with albumin in cirrhosis with refractory ascites. Hepatology 40 (2004) 629-635
18. Bureau Sr. C., Garcia-Pagan J.C., Pomier-Layrargues G., et al. Improved clinical outcome using polytetrafluroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology 126 (2004) 469-475
19. Angermayr B., Cejna M., Karnel F., et al. Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. Gut 52 (2003) 879-885
20. Azoulay D., Castaing D., Dennison A., et al. Transjugular intrahepatic shunt worsens the hyperdynamic circulatory state of the cirrhotic patient: preliminary report of a prospective study. Hepatology 19 (1994) 129-132
21. Bories P., Garcia-Compean D., Michel H., et al. The treatment of refractory ascites by the LeVeen shunt: a multi-center controlled trial (57 patients). J Hepatol 3 (1986) 212-218
22. Toledo C., Salmeron J.M., Rimola A., et al. Spontaneous bacterial peritonitis in cirrhosis: predictive factors of infection resolution and survival in patients treated with cefotaxime. Hepatology 17 (1993) 251-257
23. Fernandez J., Navasa M., Gomez J., et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 35 (2002) 140-148
24. Evans L.T., Kim W.R., Poterucha J.J., et al. Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites. Hepatology 37 (2003) 897-901
25. Follo A., Llovet J.M., Navasa M., et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 20 (1994) 1495-1501
26. Llach J., Rimola A., Navasa M., et al. Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: relevance of ascitic fluid protein concentration. Hepatology 16 (1992) 724-727
27. Guarner C., Sola R., Soriano G., et al. Risk of a first community-acquired spontaneous bacterial peritonitis in cirrhotics with low ascitic fluid protein levels. Gastroenterology 117 (1999) 495-499
28. Sola R., Andreu M., Coll S., et al. Spontaneous bacterial peritonitis in cirrhotic patients treated using paracentesis or diuretics: results of a randomized study. Hepatology 21 (1995) 340-344
29. Rimola A., Salmeron J.M., Clemente G., et al. Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: results of a prospective, randomized, multicenter study. Hepatology 23 (1996) 941-942
30. Castellote J., Lopez C., Gornals J., et al. Rapid diagnosis of spontaneous bacterial peritonitis by use of reagent strips. Hepatology 37 (2003) 745-747
31. Rimola A., Garcia-Tsao G., Navasa M., et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol 32 (2000) 142-153
32. Ricart E., Soriano G., Novella M.T., et al. Amoxicillin-clavulanic acid versus cefotaxime in the therapy of bacterial infections in cirrhotic patients. J Hepatol 32 (2000) 596-602
33. Angeli P., Guarda S., Fasolato S., et al. Switch therapy with ciprofloxacin vs. Intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost. Aliment Pharmacol Ther 23 (2006) 75-84
34. Sort P., Navasa M., Arroyo V., et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 341 (1999) 403-409
35. Fernandez J., Navasa M., Garcia-Pagan J.C., et al. Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis. J Hepatol 41 (2004) 384-390
36. Fernandez J., Monteagudo J., Bargallo X., et al. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 42 (2005) 533-535
37. Tito L., Rimola A., Gines P., et al. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology 8 (1988) 27-31
38. Gines P., Rimola A., Planas R., et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 12 (1990) 716-724
39. Bernard B., Grange J.D., Khac E.N., et al. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 29 (1999) 1655-1661
40. Hou M.C., Lin H.C., Liu T.T., et al. Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial. Hepatology 39 (2004) 746-753
41. Grange J.D., Roulot D., Pelletier G., et al. Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial. J Hepatol 29 (1998) 490-494
42. Fernandez J., Ruiz del Arbol L., Gomez C., et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology 131 (2006) 1049-1056 [quiz: 1285]
43. Adachi J.A., and DuPont H.L. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. Clin Infect Dis 42 (2006) 541-547 [Epub 2006 Jan 17]. erratum in: Clin Infect Dis 2006;42:896
44. DuPont H.L., and Jiang Z.D. Influence of rifaximin treatment on susceptibility of intestinal gram-negative flora and enterococci. Clin Microbiol Infect 10 (2004) 1009-1011
45. Gonzalez-Suarez B., Guarner C., Villanueva C., et al. Pharmacologic treatment of portal hypertension in the prevention of community-acquired spontaneous bacterial peritonitis. Eur J Gastroenterol Hepatol 18 (2006) 49-55
46. Sandhu B.S., Gupta R., Sharma J., et al. Norfloxacin and cisapride combination decreases the incidence of spontaneous bacterial peritonitis in cirrhotic ascites. J Gastroenterol Hepatol 20 (2005) 599-605
47. Taniguchi E., Kawaguchi T., Shimada M., et al. Branched-chain amino acid supplementation complements conventional treatment for spontaneous bacterial peritonitis. Dig Dis Sci 51 (2006) 1057-1060
48. Sheer T.A., and Runyon B.A. Spontaneous bacterial peritonitis. Dig Dis 23 (2005) 39-46
49. Merli M., Nicolini G., Angeloni S., et al. Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol 38 (2003) 266-272
50. North Italian Endoscopic Club (NIEC) for the study and treatment of esophageal varices, prevention of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter trial. N Engl J Med 319 (1988) 983-989
51. Eisen G.M., Eliakim R., Zaman A., et al. The accuracy of PillCam ESO capsule endoscopy versus conventional upper endoscopy for the diagnosis of esophageal varices: a prospective three-center pilot study. Endoscopy 38 (2006) 31-35
52. de Franchis R. Updating consensus in portal hypertension: report of the Baveno III Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol 33 (2000) 846-852
53. Pagliaro L., D'Amico G., Pasta L., et al. Portal hypertension in cirrhosis. Natural history. In: Bosch J., and Groszmann R.J. (Eds). Portal hypertension, pathophysiology, and treatment (1994), Blackwell Scientific, Oxford (UK) 72-92
54. De Franchis R. Evaluation and follow-up of patients with cirrhosis and oesophageal varices. J Hepatol 38 (2003) 361-363
55. D'Amico G., Pagliaro L., and Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 19 (1999) 475-505
56. Merkel C., Marin R., Angeli P., et al. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology 127 (2004) 476-484
57. Garcia-Pagan J., Morillas R.M., Bañares R., et al. Propranolol plus placebo vs propranolol plus isosorbide-5-mononitrate in the prevention of the first variceal bleed. A double blind RCT. Hepatology 37 (2003) 1260-1266
58. Jutaba R., Jensen D.M., Martin P., et al. Randomized study comparing banding and propanolol to prevent initial variceal hemorrhage in cirrhotics with high-risk esophageal varices. Gastroenterology 128 (2005) 870-881
59. Khuroo M.S., Khuroo N.S., Farahat K.L., et al. Meta-analysis: endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleeding. Aliment Pharmacol Ther 21 (2005) 347-361
60. de la Pena J., Brullet E., Sanchez-Hernandez E., et al. Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding. Multi-center trial. Hepatology 41 (2005) 572-578
61. de Franchis R., and Primignani M. Endoscopic treatments for portal hypertension. Semin Liver Dis 19 (1999) 439-455
62. Burroughs A.K., and Vangeli M. Transjugular intrahepatic portosystemic shunt versus endoscopic therapy: randomized trials for secondary prophylaxis of variceal bleeding: an updated meta-analysis. Scand J Gastroenterol 37 (2002) 249-252
63. Escorsell A., Banares R., Garcia-Pagan J.C., et al. TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trial. Hepatology 35 (2002) 385-392
64. Chao Y., Lin H.C., Lee F.Y., et al. Hepatic hemodynamic features in patients with esophageal or gastric varices. J Hepatol 19 (1993) 85-89
65. Rosemurgy A.S., Serafini F.M., Zweibel B.R., et al. Transjugular intrahepatic portosystemic shunt vs. small-diameter prosthetic H-graft portacaval shunt: extended follow-up of an expanded randomized prospective trial. J Gastrointest Surg 4 (2000) 589-597
66. Henderson J.M., Boyer T.D., Kutner M.H., et al. DSRS vs TIPS for refractory variceal bleeding: a prospective randomized controlled trial. Hepatology 40 (2004) 725A
67. Sarin S.K., Lahoti D., Saxena S.P., et al. Prevalence, classification and natural history of gastric varices: a long-term follow-up study in 568 portal hypertension patients. Hepatology 16 (1992) 1343-1349
68. Panes J., Teres J., Bosch J., et al. Efficacy of balloon tamponade in treatment of bleeding gastric and esophageal varices. Results in 151 consecutive episodes. Dig Dis Sci 33 (1988) 454-459
69. Huang Y.H., Yeh H.Z., Chen G.H., et al. Endoscopic treatment of bleeding gastric varices by N-butyl-2- cyanoacrylate (Histoacryl) injection: long-term efficacy and safety. Gastrointest Endosc 52 (2000) 160-167
70. Lo G.H., Lai K.H., Cheng J.S., et al. A prospective, randomized trial of butyl cyanoacrylate injection versus band ligation in the management of bleeding gastric varices. Hepatology 33 (2001) 1060-1064
71. Sarin S.K., Jain A.K., Jain M., et al. A randomized controlled trial of cyanoacrylate versus alcohol injection in patients with isolated fundic varices. Am J Gastroenterol 97 (2002) 1010-1015
72. Chau T.N., Patch D., Chan Y.W., et al. Salvage transjugular intrahepatic portosystemic shunts: gastric fundal compared with esophageal variceal bleeding. Gastroenterology 114 (1998) 981-987
73. Barange K., Peron J.M., Imani K., et al. Transjugular intrahepatic portosystemic shunt in the treatment of refractory bleeding from ruptured gastric varices. Hepatology 30 (1999) 1139-1143
74. Yang W.L., Tripathi D., Therapondos G., et al. Endoscopic use of human thrombin in bleeding gastric varices. Am J Gastroenterol 97 (2002) 1381-1385
75. Ginès A., Escorsell A., and Ginès P. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 105 (1993) 229-236
76. Ginès P., Rodés J., et al. Clinical disorders of renal function in cirrhosis with ascites. In: Arroyo V., Ginès P., and Rodés J. (Eds). Ascites and renal dysfunction in liver disease: pathogenesis, diagnosis, and treatment (1999), Blackwell Science, Malden (MA) 36-62
77. Rodés J., Arroyo V., and Bosch J. Clinical types and drug therapy of renal impairment in cirrhosis. Postgrad Med J 51 (1975) 492-497
78. Gonwa T.A., Morris C.A., Goldstein R.M., et al. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome: experience in 300 patients. Transplantation 51 (1991) 428-430
79. Gonwa T.A., Klintmalm G.B., Jennings L.S., et al. Impact of pre-transplant renal function on survival after liver transplantation. Transplantation 59 (1995) 361-365
80. Duvoux C., Zanditenas D., and Hezode C. Effects of noradrenaline and albumin in patients with type 1 hepatorenal syndrome: a pilot study. Hepatology 36 (2002) 374-380
81. Moreau R., Durand F., and Poynard T. Terlipressin in patients with cirrhosis and type y HRS: a retrospective multicenter study. Gastroenterology 122 (2002) 923-930
82. Fabrizi F., Dixit V., and Martin P. Meta-analysis: Terlipressin therapy for hepatorenal syndrome. Aliment Pharmacol Ther 24 (2006) 935-944
83. Angeli P., Volpin R., and Gerunda G. Reversal of type 1 HRS with the administration of midodrine and octreotide. Hepatology 29 (1999) 1690-1697
84. Pomier-Layrargues G., Paquin S.C., Hassoun Z., et al. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology 38 (2003) 238-243
85. Brensing K.A., Textro J., and Perz J. Long-term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant patients with hepatorenal syndrome: a phase II study. Gut 47 (2000) 288-295
86. Guevara M., Ginés P., and Bandi J.C. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 28 (1998) 416-422
87. Wong F., Pantea L., and Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 40 (2004) 55-64
88. Mitzner S.R., Stange J., and Klammt S. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 6 (2000) 277-286
89. Jalan R., Sen S., Steiner C., et al. Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. J Hepatol 38 (2003) 24-31
90. Akriviadis E., Botla R., Briggs W., et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 119 (2000) 1637-1648
91. Benjaminov F.S., Prentice M., Sniderman K.W., et al. Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. Gut 52 (2003) 1355-1362
92. Kawut S.M., Taichman D.B., Ahya V.N., et al. Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transpl 11 (2005) 1107-1111
93. Starkel P., Vera A., Gunson B., et al. Outcome of liver transplantation for patients with pulmonary hypertension. Liver Transpl 8 (2002) 382-388
94. Krowka M.J., Plevak D.J., Findlay J.Y., et al. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 6 (2000) 443-450
95. Krowka M.J., Swanson K.L., Frantz R.P., et al. Portopulmonary hypertension: results from a 10-year screening algorithmn. Hepatology 44 (2006) 1502-1510
96. Sussman N., Kaza V., Barshes N., et al. Successful liver transplantation following medical management of portopulmonary hypertension: a single-center series. Am J Transplant 6 (2006) 2177-2182
97. Krowka M.J., Frantz R.P., McGoon M.D., et al. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 30 (1999) 641-648
98. Minder S., Fischler M., Muellhaupt B., et al. Intravenous iloprost bridging to orthotopic liver transplantation in portopulmonary hypertension. Eur Respir J 24 (2004) 703-707
99. Hoeper M.M., Halank M., Mark C., et al. Bosentan for treatment of portopulmonary hypertension. Eur Respir J 25 (2005) 502-508
100. Reichenberger F., Voswinckel R., Steveling E., et al. Sildenafil treatment for portopulmonary hypertension. Eur Respir J 28 (2006) 563-567
101. Provencher S., Herve P., and Jais X. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 130 (2006) 120-126
102. Kao P.N. Simvastatin treatment for pulmonary hypertesion. Chest 127 (2005) 1446-1452
103. Martinez G., Barbera J., Visa J., et al. Hepatopulmonary syndrome in candidates for liver transplantation. J Hepatol 34 (2001) 756-758
104. Binay K., Sen S., Biswas P.K., et al. Hepatopulmonary syndrome in inferior vena cava obstruction responding to cavoplasty. Gastroenterology 118 (2000) 192-196
105. Gupta D., Vijaya D.R., Gupta R., et al. Prevalence of hepatopulmonary syndrome in cirrhosis and extrahepatic portal venous obstruction. Am J Gastroenterol 96 (2001) 3395-3399
106. Schenk P., Schoniger-Hekele M., Fuhrmann V., et al. Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology 125 (2003) 1042-1052
107. Abrams G.A., Jaffe C.C., Hoffer P.B., et al. Diagnostic utility of contrast echocardiography and lung perfusion scan in patients with hepatopulmonary syndrome. Gastroenterology 109 (1995) 1283-1288
108. Abrams G., Nanda N., Dubovsky E., et al. Use of macroaggregated albumin lung perfusion scan to diagnose hepatopulmonary syndrome: a new approach. Gastroenterology 114 (1998) 305-310
109. Lima B.L., Franca A.V., Pazin-Filho A., et al. Frequency, clinical characteristics, and respiratory parameters of hepatopulmonary syndrome. Mayo Clin Proc 79 (2004) 42-48
110. Arguedas M., Abrams G.A., Krowka M.J., et al. Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation. Hepatology 37 (2003) 192-197
111. Sulieman B., Voigt M., Katz D., et al. Data driven policy for points allocation in hepatopulmonary syndrome. Hepatology 42 (2005) 347A
112. Henrion J., Schapira M., Luwaert R., et al. Hypoxic hepatitis: clinical and hemodynamic study in 142 consecutive cases. Medicine (Baltimore) 82 (2003) 392-406
113. Selim K.M., Akriviadis E.A., Zuckerman E., et al. Transjugular intrahepatic portosystemic shunt: a successful treatment for hepatopulmonary syndrome. Am J Gastroenterol 93 (1998) 455-458
114. Allgaier H.P., Haag K., Ochs A., et al. Hepatopulmonary syndrome: successful treatment by transjugular intrahepatic portosystemic stent-shunt (TIPS). J Hepatol 23 (1995) 102-105
115. Paramesh A., Hussain S., Shneider B., et al. Improvement of hepatopulmonary syndrome after transjugular intrahepatic portasystemic shunting: case report and review of literature. Pediatr Transplant 7 (2003) 157-162
116. Chevallier P., Novelli L., Motamedi J.P., et al. Hepatopulmonary syndrome successfully treated with transjugular intrahepatic portosystemic shunt: a three-year follow-up. J Vasc Interv Radiol 15 (2004) 647-648
117. Martinez-Palli G., Drake B.B., Garcia-Pagan J.C., et al. Effect of transjugular intrahepatic portosystemic shunt on pulmonary gas exchange in patients with portal hypertension and hepatopulmonary syndrome. World J Gastroenterol 11 (2005) 6858-6862
118. Navasa M., Rimola A., and Rodés J. Bacterial infections in liver disease. Semin Liver Dis 17 (1997) 323-333
119. Duchini A., Viernes M.E., Nyberg L.M., et al. Hepatic decompensation in patients with cirrhosis during infection with influenza A. Arch Intern Med 160 (2000) 113-115
120. Gaeta G.B., Stornaiuolo G., Precone D.F., et al. Immunogenicity and safety of an adjuvanted influenza vaccine in patients with decompensated cirrhosis. Vaccine 20 (2002) B33-B35
121. Cheong H.J., Song J.Y., Park J.W., et al. Humoral and cellular immune responses to influenza vaccine in patients with advanced cirrhosis. Vaccine 24 (2006) 2417-2422
122. McCashland T.M., Preheim L.C., and Gentry M.J. Pneumococcal vaccine response in cirrhosis and liver transplantation. J Infect Dis 181 (2000) 757-760
123. Arguedas M.R., McGuire B.M., and Fallon M.B. Implementation of vaccination in patients with cirrhosis. Dig Dis Sci 47 (2002) 384-387
124. Keeffe E.B. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases?. Am J Gastroenterol 90 (1995) 201-205
125. Yao G. Clinical spectrum and natural history of viral hepatitis in a 1988 Shanghai epidemic. In: Hollinger F.B., Lemon S.M., and Margolis H. (Eds). Viral hepatitis and liver disease (1991), Lippincott Williams & Wilkins, Baltimore (MD) 76-78
126. Fukumoto Y., Okita K., Konishi T., et al. Hepatitis A infection in chronic carriers of hepatitis B virus. In: Sung J.-L., and Chen D.-S. (Eds). Viral hepatitis and hepatocellular carcinoma (1990), Excerpta Medica, Amsterdam 43-48
127. Papachristou A.A., Dumas A.S., and Katsouyannopoulos V.C. Dissociation of alanine aminotransferase values in acute hepatitis A patients with and without past experience to the hepatitis B virus. Epidemiol Infect 106 (1991) 397-402
128. Vento S., Garofano T., Renzini C., et al. Fulminant hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C. N Engl J Med 338 (1998) 286-290
129. Féray C., Gigou M., Samuel D., et al. Hepatitis C virus RNA and hepatitis B virus DNA in serum and liver of patients with fulminant hepatitis. Gastroenterology 104 (1993) 549-555
130. Mohamed Ael S., al Karawi M.A., and Mesa G.A. Dual infection with hepatitis C and B viruses: clinical and histological study in Saudi patients. Hepatogastroenterology 44 (1997) 1404-1406
131. Saab S., Lee C., Shpaner A., et al. Seroepidemiology of hepatitis A in patients with chronic liver disease. J Viral Hepat 12 (2005) 101-105
132. Arguedas M.R., Johnson A., Eloubeidi M.A., et al. Immunogenicity of hepatitis A vaccination in decompensated cirrhotic patients. Hepatology 34 (2001) 28-31
133. Smallwood G.A., Coloura C.T., Martinez E., et al. Can patients awaiting liver transplantation elicit an immune response to the hepatitis A vaccine?. Transplant Proc 34 (2002) 3289-3290
134. Dominguez M., Barcena R., Garcia M., et al. Vaccination against hepatitis B virus in cirrhotic patients on liver transplant waiting list. Liver Transpl 6 (2000) 440-442
135. Arslan M., Wiesner R.H., Sievers C., et al. Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease. Liver Transpl 7 (2001) 314-320
136. Guichelaar M., Hay J., Clark B., et al. Pretransplant bone histomorphometric status of patients with end-stage cholestatic liver disease. J Hepatol 32 (2000) 54
137. Carey E.J., Balan V., Kremers W.K., et al. Osteopenia and osteoporosis in patients with end-stage liver disease caused by hepatitis C and alcoholic liver disease: not just a cholestatic problem. Liver Transpl 9 (2003) 1166-1173
138. Reid I., Brown J.P., Burckhardt P., et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346 (2002) 653-661
139. Reeves H., Francis R., Manas D.M., et al. Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation. Liver Transpl Surg 4 (1998) 404-409